<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/css" href="https://imcjms.com/assets/rss.css" ?><rss version="2.0">
<channel>
    <title>IMC Journal of Medical Science</title>
    <link>https://imcjms.com</link>
    <description>Ibrahim Medical College Journal of Medical Science</description>

                        <item>
                <title><![CDATA[Bacterial
co-infection in Covid-19 patients visiting a tertiary care hospital in
Maharashtra]]></title>

                                    <author><![CDATA[Rajashri Patil]]></author>
                                    <author><![CDATA[Rakshit Pandey]]></author>
                                    <author><![CDATA[Nageswari Gandham]]></author>
                                    <author><![CDATA[Shahzad Mirza]]></author>
                                    <author><![CDATA[Chanda Vyawahare]]></author>
                                    <author><![CDATA[Sameena Khan]]></author>
                                    <author><![CDATA[Jyoti Ajagunde]]></author>
                                    <author><![CDATA[Nikunja Kumar Das]]></author>
                                    <author><![CDATA[Sahjid Mukhida]]></author>
                
                <link data-url="https://imcjms.com/registration/journal_full_text/458">
    https://imcjms.com/registration/journal_full_text/458
</link>
                <pubDate>Wed, 12 Apr 2023 12:58:28 +0000</pubDate>
                <category><![CDATA[Original Article]]></category>
                <comments><![CDATA[IMC J Med Sci. 2023; 17(2):006]]></comments>
                <description>Abstract
Background and objectives:
Several patients with SARS-CoV-2 infection presents with bacterial
co-infection. The aim of the present study was to determine the bacteria
responsible for co-infection in Covid-19 infected patients visiting a tertiary
care hospital of Maharashtra, India.
Material and methods:
A cross sectional study was conducted for 3 months at tertiary care center. Covid-19
patients attending the hospital were included in the study. All the specimens were collected
either at the time of admission at outdoor or within 24-48 hours of admission. All
the specimens were processed for culture and antibiotic susceptibility testing
as per institutional policy and standard methods.
Results:
Total 200 samples were
collected out of which 98 (49%) patients were diagnosed
with bacterial co-infection. Majority of cases with bacterial co-infection were above 21 years of
age. Culture was positive in 80%, 66.7%, 49.2% and 38.8% of tracheal aspirate,
pus, blood and urine samples respectively. Out of 98 cases of bacterial
co-infection, 62.2% and 37.8% had infection with Gram negative and positive
bacteria respectively. Most common organism isolated was Klebsiella
pneumoniae (20.4%) followed by Enterococcus species (14.3%). Over 70% of Klebsiella
pneumoniae isolates were resistant to aminoglycosides, cephalosporins,
fluroquinolones and carbapenems while 100% Acinetobacter was resistant to all antimicrobials
tested. Among 57 Of the Gram negative isolates, 5 and 24 isolates were positive
for ESBL carbapenemase respectively.
Conclusion: The study revealed that bacterial co-infection was
present in considerable proportion of Covid-19 patients and the organisms
responsible were resistant to several antimicrobial agents.
IMC
J Med Sci. 2023; 17(2):006. DOI: https://doi.org/10.55010/imcjms.17.016
*Correspondence:
Sahjid Mukhida, Department
of Microbiology, Dr. D. Y. Patil Medical College, Hospital and Research Centre,
Dr. D. Y. Patil Vidyapeeth, Pimpri, Pune, Maharashtra, India-411018. E-mail: drssmukhida@rediffmail.com
&amp;nbsp;
Introduction
The novel coronavirus
first emerged in Wuhan, China, in December 2019 and has led to a global
pandemic and as of May, 2022, about 500 million cases and
more than 6 million deaths have been recorded around the world [1]. People with underlying morbidities are more
susceptible to complications [2]. However, healthy individuals experience a
mild flu-like illness or may be asymptomatic, recuperating from the infection
even without any particular intervention [3]. Multiple studies have
reported a correlation between SARS-CoV-2 infection and bacterial co-infections/superinfections
[4-8]. About 20% of patients with SARS-CoV-2 are presented with co-infection,
while 41% of superinfections were found among the ICU patients [7]. Therefore,
antimicrobial agents are frequently used in cases of Covid-19 disease. The
availability of bacterial and antimicrobial resistance profiles is important
for rational prescription of antibiotics to treat Covid-19 patients effectively.
However, data regarding types of bacteria causing co-infections and their
antimicrobial resistance profiles are lacking. So, the present study was undertaken
to determine the bacteria responsible for co-infection in Covid-19 patients
visiting a tertiary care hospital in Maharashtra, India. 
&amp;nbsp;
Material
and methods
This cross sectional study was
conducted for 3 months from January to March 2022 at a tertiary care hospital
of western Maharashtra. The study was approved by the institutional ethical
committee prior to the initiation of the study (Ethical approval letter No.
I.E.S.C./31/2022).
Study population and sample collection:
Covid-19 patient attending the outpatient department or admitted in the
hospital were included in the study. Covid-19 was defined if a case was
positive for SARS-CoV-2 either by RT-PCR or rapid antigen test or both. Detailed
history regarding age, sex, associated conditions,
and antibiotic, steroid, or antiviral therapies was taken from the
enrolled patients. All
the specimens were collected within 24-48 hours of admission. None of the
sample was collected after 48 hours of hospital admission to exclude patient with
hospital acquired infection in our current study sample. Samples from patients
attending the outpatient were collected at the time of visit or admission of
the patients. Samples for the culture were collected aseptically
only from those who had suspected co-infection(s).
Sample processing:
All the collected
specimens were processed for culture as per institutional policy and standard
methods. Specimens were cultured on blood agar, MacConkey agar, Cystine-Lactose-Electrolytes-Deficient
(CLED) agar by streaking methods and incubated at 37°C for 18-24 hours. Blood
specimen was collected in automated BacT/Alert blood culture bottle and
incubated at 370C for up to 7 days. Positive sample was sub-cultured
on blood agar, MacConkey agar and incubate for 18 -24 hours. Suspected colonies
were identified by Gram stain, motility, catalase, oxidase, coagulase and other
standard biochemical tests [9]. All bacterial isolates were tested for
antibiotic susceptibility using Kirby Bauer disc diffusion method on
Mueller-Hinton agar plates. Isolated colonies were inoculated by lawn culture
and antibiotic discs were placed on the surface and the plates were kept for
incubation for 18-24 hours. The zone of inhibition was interpreted following
the CLSI 2022 guidelines [10]. Automated Vitek 2C was used for identification
of organism and antibiotic susceptibility testing as and when required. Extended
spectrum Beta lactamase (ESBL) and carbapenemase production were detected by double
disc diffusion method and modified Hodge test respectively [11,12]. 
&amp;nbsp;
Results
Total 200 samples were collected and out of which 98 (49%) specimens yielded
bacterial growth. Out of 200 cases, Gram
negative and positive bacteria were isolated from 61 (30.5%) and 37 (18.5%)
cases respectively and 86 (43%) had infection in single site and in 12 (6%)
cases bacteria were isolated from more than one anatomical sites. 
The rate of culture positivity was 45.9% and 55.4% in male and female
patients respectively while the rates ranged from 55.7% - 37.7% in samples
collected from outdoor, indoor and ICU. Majority of cases belonged to 21 years
to above 60 years of age. Culture was positive in 80%, 66.7%, 49.2% and 38.8%
of tracheal aspirate, pus, blood and urine samples respectively. Only 30 (15%)
patients had comorbidities and of them 6 (20%) had co-infection (Table-1). 
&amp;nbsp;
Table-1: Detail characteristics of the study population (N=200)
&amp;nbsp;
&amp;nbsp;
Table-2 shows the pattern of bacteria isolated from different samples of
Covid-19 patients. Overall, out of 98 cases of bacterial co-infection, 61 (61/98=62.2%)
had infection with Gram negative bacteria while 37 (37/98=37.8%) was infected
with Gram positive bacteria. Except pus, other specimens yielded mostly (55%-100%)
growth of Gram negative organisms. Out of 14 pus samples, 9 (64.3%) showed
growth of Gram positive bacteria. Most common organism isolated from the
covid-19 patients was Klebsiella pneumoniae (20.4%) followed by Enterococcus
species (14.3%), Staphylococcus
aureus and Pseudomonas sp (each 12.2%) Less common isolates were
Proteus sp, Elizabethkingia meningoseptica and Aerococcus viridans.
&amp;nbsp;
Table-2: Pattern of
bacteria isolated from different specimens of Covid-19 patients
&amp;nbsp;
&amp;nbsp;
Table-3 shows the detail antimicrobial resistance profile of
Gram-negative bacteria isolated from Covid-19 patients. As per the antibiotic
susceptibility testing, more than 70% of Klebsiella pneumoniae isolates
were resistant to aminoglycosides, cephalosporins, fluroquinolones and
carbapenems. All (100%) the Acinetobacter sp, Proteus sp and E. meningoseptica were
resistant to all antimicrobials tested. Among the gram-positive isolates, major
drug resistance was noted against the fluroquinolones, macrolides and
ampicillin (Table-4). None of the isolate was resistant to vancomycin and
linezolid.
&amp;nbsp;
Table-3: Antimicrobial resistance patterns of isolated Gram-negative bacteria
&amp;nbsp;
&amp;nbsp;
Table-4: Antimicrobial resistance patterns of isolated Gram-positive bacteria.
&amp;nbsp;
&amp;nbsp;
Among 61 Gram negative isolates, 57 isolates were tested for ESBL and
carbapenemase production. Out of 57 isolates 5 (8.8%) and 24 (42.1%) were
positive for ESBL and carbapenemase respectively (Table-5). Highest (58.3%)
carbapenemase production was detected in Pseudomonas
sp.
&amp;nbsp;
Table-5: Rate of ESBL
and carbapenemase producing bacteria
&amp;nbsp;
&amp;nbsp;
Discussion
In the present study, bacterial co-infection
was found in 49% patient. The rate was higher than many reported studies [13-18].
Those studies reported bacterial co-infection from 4% to 20% in Covid-19
patients. However on the contrary, Alshrefy et al [19] and Sreenath et
al [20] reported almost similar rate of bacterial co-infection (42.4% and
47.1%) like ours. Covind-19 affects all age group patients which include from
pediatric to geriatric age groups but older age group patient is infected more
compared to other age group. In the present study, there was no significant
increase of bacterial isolation rate with the increase of age. Mean age of the Covid-19
patients in current study was 47.13 years which was lower compared to various
studies done on bacterial co-infection in Covid-19 admitted patients. The
reported mean age of patients in other studies ranged from 56 to 74 years
[14,16,17,21-24]. 
Majority of the Covid-19 patients need
ventilator support as well as urinary catheterization during their ICU stay.
Due to use of various immunosuppressive drugs, ICU patients have more chance to
develop the bacterial infections. Several studies reported 28% to 83% bacterial
infection in ICU admitted Covid-19 patients [14,15,21]. In the present study,
37.7% specimens from ICU patients had positive bacterial growth.
Several studies reported Gram negative
bacteria as predominant infecting agents in Covid-19 patients. Bacterial
co-infection in Covid-19 patients due to Gram negative organism varied from 75%
to about over 90% [22,16,15] while it was around 40% by Gram positive bacteria
[16,22]. Similarly, in
the current study we also found Gram negative bacteria as the predominant
(62.2%) offending agents for causing co-infection in our Covid-19 cases. Only,
37.4% cases were infected by Gram positive bacteria. Among the Gram negative
bacteria, K. pneumoniae was the most
commonly isolated bacteria followed by Pseudomonas
and Acinetobacter species. Same types
of bacteria were most commonly isolated from Covid-19 cases by others [15,16,19,24].
As found by other studies [16,20], we also observed enterococci and S. aureus as the most commonly isolated Gram
positive bacteria.
Resistance against antimicrobial
agents is a global health burden in current time. With the extensive use of antimicrobials,
multi-drug resistant isolates have arisen globally. During the covid-19
pandemic, antibiotics are extensively used by the clinicians. Over 70% of Klebsiella
pneumonia, the most commonly
isolated bacteria in our series, was resistant to all the antimicrobial agents
tested. Similar high rate of resistance was exhibited by our isolated Acinetobacter sp and Gram positive bacteria
to several antibiotics tested. This could be due to prevalence of such drug
resistant bacteria in the local community. The increasing exposure to
healthcare environments and invasive procedures, as well as increased
antibiotic usage, raises the potential for emergence of multidrug resistant
bacteria [15,22,24]. The present study had some limitations. The study was conducted at a single center over a short
period and the sample size was small.
The present study has
demonstrated that about half of the Covid-19 cases suffer from bacterial
co-infections and many of those are caused by multidrug resistant bacteria.
However, it is still unclear what exact roles co-infections and/or super
infections play in patients with COVID-19 cases. Accurate and quick detection of
bacterial co-infection with antibiotic susceptibility testing, particularly for
severe infections, can assist clinicians to effectively treat Covid-19 patients
with better clinical outcomes.
&amp;nbsp;
Acknowledgement
The
authors would like to acknowledge the contributions of staff and laboratory
personnel of the Department of Microbiology, Dr. D.Y. Patil Medical College, Hospital
and Research Center, Pimpri, Pune, India.
&amp;nbsp;
Source
of Funding
All the tests and procedures were
carried out from institutional funds. Funds were not received from any external
agency.
&amp;nbsp;
Conflict
of Interest
None of the author has any conflict of
interest. 
&amp;nbsp;
References
1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; World
Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health
Organization; 2022.
2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Silva D, Lima C, Magalhães V, Baltazar L.
Peres N, Caligiorne R, et al. Fungal and bacterial coinfections increase
mortality of severely ill COVID-19 patients. J Hosp Infect. 2021; 113: 145–154.
&amp;nbsp;3.&amp;nbsp;&amp;nbsp;&amp;nbsp; Jose
M, Desai K. Fatal superimposed bacterial sepsis in a healthy Coronavirus
(COVID-19) patient. Cureus. 2020; 12(5):
e8350. Doi: 10.7759/cureus.8350. 
4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Phua J, Weng L, Ling L, Egi M, Lim CM,
Divatia JV, et al. Intensive care management of coronavirus disease 2019
(COVID-19): challenges and recommendations. Lancet
Respir Med. 2020;
8: 506–517. doi:&amp;nbsp;10.1016/S2213-2600(20)30161-2.
5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Elabbadi A, Turpin M, Gerotziafas GT,
Teulier M, Voiriot G, Fartoukh M. Bacterial coinfection in critically ill COVID-19
patients with severe pneumonia. Infection. 2021; 49:
559–562. doi:&amp;nbsp;10.1007/s15010-020-01553-x.
6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Garcia-Vidal C, Sanjuan G, Moreno-García E,
Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of
co-infections and superinfections in hospitalized patients with COVID-19: a retrospective
cohort study. Clin Microbiol Infect.
2020; 27: 83–88. doi:&amp;nbsp;10.1016/j.cmi.2020.07.041.
7.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Musuuza JS, Watson L, Parmasad V,
Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of
co-infection and superinfection with SARS-CoV-2 and other pathogens: a
systematic review and meta-analysis. PLoS
ONE. 2021; 16: e0251170.
doi:&amp;nbsp;org/10.1371/journal.pone.0251170.
8.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; He S, Liu W, Jiang M, Huang P, Xiang Z,
Deng D, et al. Clinical characteristics of COVID-19 patients with
clinically diagnosed bacterial co-infection: a multi-center study. PloS ONE. 2021; 16:
e0249668. doi.org/10.1371/journal.pone.0249668.
&amp;nbsp;9.&amp;nbsp;&amp;nbsp;&amp;nbsp; Winn W, Allen S, Janda W, Koneman E,
Procop G, Schreckenberger P, Woods, G. Koneman’s Color Atlas And Textbook Of
Diagnostic Microbiology. 7th Edition, Lippincott Williams and
Wilkins, New York. 2016; 804-807.
10.&amp;nbsp; Clinical
and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 32nd
Ed. CLSI Supplement M100. Wayne, PA: Clinical Laboratory Standard
Institute; 2022.
11.&amp;nbsp; Clinical
and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing.
Twenty second informational supplement update. CLSI document
M100-S22 U. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
12.&amp;nbsp; Clinical and Laboratory Standards Institute.
Screening and confirmatory tests for suspected carbapenemases production. 20
supplemental table 2A-S2. Wayne, PA:Clinical Laboratory Standard Institute;2010.
13.&amp;nbsp; Westblade
LF, Simon MS, Satlin MJ. Bacterial coinfections in Coronavirus Disease 2019. Trends
Microbiol. 2021; 29(10): 930-941.
Doi: 10.1016/j.tim.2021.03.018. 
14.&amp;nbsp; Russell
CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al.
Co-infections, secondary infections, and antimicrobial use in patients hospitalised
with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study:
a multicentre, prospective cohort study. The Lancet Microbe. 2021; 2(8): E354-E365. doi.org/10.1016/S2666-5247(21)00090-2.
15.&amp;nbsp; Pourajam
S, Kalantari E, Talebzadeh H, Mellali H, Sami R, Soltaninejad F, et al. Secondary bacterial infection and
clinical characteristics in patients with COVID-19 admitted to two intensive
care units of an academic hospital in Iran during the first wave of the
pandemic.&amp;nbsp;Front Cell Infect Microbiol.&amp;nbsp;2022; 12: 784130. doi: 10.3389/fcimb.2022.784130.

16.&amp;nbsp; Shafran
N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, et al.&amp;nbsp;Secondary
bacterial infection in COVID-19 patients is a stronger predictor for death
compared to influenza patients.&amp;nbsp;Sci Rep. 2021; 11(1): 12703.
doi.org/10.1038/s41598-021-92220-0.
17.&amp;nbsp; d’Humières
C, Patrier J, Lortat-Jacob B, Tran-dinh A, Chemali L, Maataoui N, et al.
Two original observations concerning bacterial infections in COVID-19 patients
hospitalized in intensive care units during the first wave of the epidemic in
France. PloS ONE. 2021; 16(4): e0250728. doi.org/10.1371/journal.pone.0250728.
18.&amp;nbsp; Soltani
S, Faramarzi S, Zandi M, Shahbahrami R, Jafarpour A, AkhavanRezayat S, et al.
Bacterial coinfection among coronavirus disease 2019 patient groups: an updated
systematic review and meta-analysis. New Microbes New Infect. 2021;
43:100910. doi: 10.1016/j.nmni.2021.100910.
19.&amp;nbsp; Alshrefy
AJ, Alwohaibi RN, Alhazzaa SA, Almaimoni RA, AlMusailet LI, AlQahtani SY,
Alshahrani MS. Incidence of bacterial and fungal secondary infections in
COVID-19 patients admitted to the ICU.&amp;nbsp;Int J Gen Med. 2022; 15: 7475-7485. doi.org/10.2147/IJGM.S382687.
20.&amp;nbsp; Sreenath
K, Batra P, Vinayaraj EV, Bhatia R, SaiKiran K, Singh V, et al.
Coinfections with other respiratory pathogens among patients with COVID-19. Microbiol
Spectr. 2021; 9(1): e0016321. doi:
10.1128/Spectrum.00163-21. 
21.&amp;nbsp; Bazaid
AS, Barnawi H, Qanash H, Alsaif G, Aldarhami A, Gattan H, et al.
Bacterial coinfection and antibiotic resistance profiles among hospitalised COVID-19
patients. Microorganisms. 2022; 10(3):
495. doi.org/10.3390/microorganisms10030495.
22.&amp;nbsp; Saeed NK, Al-Khawaja S, Alsalman, J, Almusawi S,
Albalooshi NA, Al-Biltagi M. Bacterial co-infection in patients with SARS-CoV-2
in the Kingdom of Bahrain.&amp;nbsp;World J Virol.&amp;nbsp;2021;
10: 168–181.
23.&amp;nbsp; Moreno-García
E, Puerta-Alcalde P, Letona L, Meira F, Dueñas G, Chumbita M, et al.
Bacterial co-infection at hospital admission in patients with COVID-19. Int
J Infect Dis. 2022; 118: 197-202.
doi: 10.1016/j.ijid.2022.03.003. 
24.&amp;nbsp; Li
J, Wang J, Yang Y, Cai P, Cao J, Cai X, Zhang Y. Etiology and antimicrobial
resistance of secondary bacterial infections in patients hospitalized with
COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect
Control. 2020; 9(1): 153. doi:
10.1186/s13756-020-00819-1
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;
&amp;nbsp;&amp;nbsp;
Cite this article as:
Patil
R, Pandey
R, Gandham N, Mirza S, Vyawahare C, Khan S, Ajagunde J, Das NK, Mukhida S. Bacterial co-infection in Covid-19&amp;nbsp; patients visiting a tertiary care hospital in
Maharashtra. IMC
J Med Sci. 2023; 17(2): 006. DOI: https://doi.org/10.55010/imcjms.17.016</description>

            </item>
            
    <copyright>2026 Ibrahim Medical College. All rights reserved.</copyright>
</channel>
</rss>
